NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday, 14 July 2022

**Location:** Via Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for items 3, 4, 5, 6, 7, 9, 10, and 11
2. Professor Colin Howie [Vice Chair] Present for all items
3. Dr Charlotta Karner Present for all items
4. Ms Dawn Lee Present for all items
5. Professor Dhiraj Tripathi Present for all items
6. Dr Duncan McPherson Present for all items
7. Mr Jonathan Anderson Present for all items
8. Dr Jurjees Hasan Present for all items
9. Miss Karen Nugent Present for all items
10. Mr Kieran Murphy Present for items 5, 6, 7, 8, 9, 10, and 11
11. Mr Mahmoud Elfar Present for all items
12. Mr Marwan Habiba Present for all items
13. Professor Matt Bown Present for items 3, 5, 6, 7, 8, 9, 10, and 11
14. Mrs Sally Brearley Present for items 3, 4, 5, 6, 7, and 8
15. Dr Stuart Smith Present for all items
16. Dr Tim Kinnaird Present for items 3, 4, 5, 6, 7, 8, and 9
17. Ms Veena Soni Present for items 3, 4, 5, 6, and 7

# Committee Apologies:

1. Mr James Tysome
2. Dr Jon Bell
3. Ms Maria Parsonage
4. Mr Matthew Metcalfe
5. Dr Ruchika Gupta
6. Professor Tim Jackson

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Anastasia Chalkidou, Associate Director, IPP

Anna Sparshatt - Senior Editor, Publishing Team

Charlie Campion – Project Manager, IPP

Deonee Stanislaus – Coordinator, IPP

Emilene Coventry - Senior Medical Editor, Publishing Team

Emma Gordon - Coordinator, Corporate Office

Emma McCarthy – Associate Health Technology Assessment Analyst, IPP

Hayley Garnett - Senior Medical Editor, Publishing Team

Helen Crosbie - Public Involvement Adviser, Public Involvement Programme

Helen Gallo – Senior Health Technology Assessment Analyst, IPP

Professor John Powell – Consultant Clinical Advisor, IPP

Professor Kevin Harris – Programme Director & Consultant Clinical Advisor, IPP

Lakshmi Mandava – Health Technology Assessment Analyst, IPP

Lyn Davies – Coordinator, Corporate Office

Tom Palmer – Health Technology Assessment Analyst, IPP

Xia Li – Health Technology Assessment Analyst, IPP

Zoe Jones – Administrator, IPP

# External group representatives present:

Harvey Galvin, Senior Manager – Market Access, AngioDynamics Present for items #3

Reinhard Krickl, Chief Executive Officer, Phagenesis Present for items #5

Conor Mulrooney, Chief Operating Officer, Phagenesis Present for items #5

Jason Hanon, CEO, Mainstay Medical International plc Present for items #6

Dr Chris Gilligan, Associate Chief Medicial Officer, Mainstay Medical International plc Present for items #6

Vanessa Malka, Executive Director iTind Commercial Head, Olympus Medical Present for items #7

Joshua Hicks, Manager – Health Economics & Market Access (HEMA), Olympus Medical Present for items #7

# Clinical & patient experts present:

Professor Mark Emberton, Dean UCL Faculty of Medical Sciences, UCL and UCLH NHS Trust Present for items #3

Colin Nice, Consultant Interventional Radiologist, Newcastle Upon Tyne NHS Foundation Trust Present for items #4

Deborah Broadbent, Clinical Speech and Language Therapist, University Hospitals Dorset Present for items #5

Professor Philip Bath, Stroke Association Professor of Stroke Medicine, University of Nottingham Present for items #5

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None.
3. NNP of IP1020/2 Irreversible electroporation for treating prostate cancer
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from AngioDynamics.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Dhiraj Tripathi, who gave a presentation on the safety and efficacy of Irreversible electroporation for treating prostate cancer.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 10:06am.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1857 Percutaneous thoracic duct embolization for persistent chyle leak
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives and members of the public.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Karen Nugent, who gave a presentation on the safety and efficacy of Percutaneous thoracic duct embolization for persistent chyle leak.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 11:43am.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1877 Electrical stimulation of the pharynx for neurogenic dysphagia
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Phagenesis.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Mahmoud Elfar, who gave a presentation on the safety and efficacy of Electrical stimulation of the pharynx for neurogenic dysphagia.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 13:02pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1790 Restorative Neurostimulation to Activate the Lumbar Multifidus for chronic mechanical low back pain
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Mainstay Medical International plc.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Jurjees Hasan, who summarised the comments received during the consultation on the draft guidance for Restorative Neurostimulation to Activate the Lumbar Multifidus for chronic mechanical low back pain.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 14:40pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1701/2 Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Olympus Medical.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Colin Howie, who summarised the comments received during the consultation on the draft guidance for Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 15:10pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1804 Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives and members of the public.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* Tom Clutton-Brock declared a non-financial professional and personal interest as his employer has been involved in research around this procedure.
* It was agreed that his declaration would prevent Tom Clutton-Brock from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Vice Chair then introduced Jon Anderson, who summarised the comments received during the consultation on the draft guidance for Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause.
		2. The Vice Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 15:27pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP1937 Vaginal natural orifice transluminal endoscopic surgery for hysterectomy and adnexal surgery
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Marwan Habiba, who gave a presentation on the safety and efficacy of Vaginal natural orifice transluminal endoscopic surgery for hysterectomy and adnexal surgery.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Briefs of IP1934 Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* Matt Bown declared a non-financial professional and personal interest as the unit he works in is one of the UK sites for the Promise study.
* It was agreed that his declaration would not prevent Matt Bown from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Matt Bown, who gave a presentation on the safety and efficacy of Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Briefs of IP1359 Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Jon Anderson, who gave a presentation on the safety and efficacy of Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 11/08/2022 and will start promptly at 9am.